SHAREHOLDER NOTICE:  Brodsky & Smith, LLC Announces an Investigation of Oclaro, Inc.- OCLR


BALA CYNWYD, March 19, 2018 /Access Wire/ – Law office of Brodsky & Smith, LLC announces that it is investigating potential claims against the Board of Directors of Oclaro, Inc. (“Oclaro” or “the Company”) (Nasdaq- OCLR-News) for possible breaches of fiduciary duty and other violations of federal and state law in connection with the sale of the Company to Lumentum Holdings Inc. (“Lumentum”).

Under the terms of the transaction, Oclaro shareholders will receive only $5.60 in cash and 0.0636 of a share of Lumentum for each share of Oclaro stock they own. The transaction values Oclaro at only $9.99 per share. The investigation concerns whether the Board of  Oclaro breached their fiduciary duties to shareholders and whether Lumentum is underpaying for the Company. The transaction may undervalue the Company and may not be in the Oclaro shareholders best interests. For example, the transaction will result in no real gain for many shareholders as Oclaro stock has recently traded at $9.82 per share and an analyst has set a $12.00 per share price target for the stock.

If you own shares of Oclaro stock and wish to discuss the legal ramifications of  the investigation, or have any questions, you may e-mail or call the law office of Brodsky & Smith, LLC who will, without obligation or cost to you, attempt to answer your questions. You may contact Jason L. Brodsky, Esquire or Evan J. Smith, Esquire at Brodsky & Smith, LLC, Two Bala Plaza, Suite 510, Bala Cynwyd, PA  19004, or calling toll free 877-LEGAL-90.

Brodsky & Smith, LLC is a litigation law firm with extensive expertise representing shareholders throughout the nation in securities and class action lawsuits. The attorneys at Brodsky & Smith have been appointed by numerous courts throughout the country to serve as lead counsel in class actions and have successfully recovered millions of dollars for our clients and shareholders. Attorney advertising. Prior results do not guarantee a similar outcome.